Comparative investigation of efficacy of epirubicin joint docetaxel for triple-negative and non-triple-negative breast cancer

Abstract

Objective To investigate clinical efficacy of epirubicin joint docetaxel for triple-negative and non-triple-negative breast cancer, to provide reference for clinical treatment. Methods A retrospective analysis of 80 cases with breast cancer was conducted, 26 patients with triple-negative breast cancer were set as study group, and 54 patients with non-triple negative breast cancer were set as control group.All patients used epirubicin docetaxel chemotherapy, the curative effect, survival rate, toxicity were compared between the two groups. Results The chemotherapy response rate of triple-negative breast cancer group was 84.62%, which was significantly higher than 53.70% in non-triple-negative breast cancer group (χ2=6.45, P<0.01). The 5-year disease-free survival rate, overall survival rate of triple-negative breast cancer group were 50.00%, 73.08%, which were significantly lower than those of non-triple-negative breast cancer group (χ2=5.89, P<0.01; χ2=4.19, P<0.01). The incidence rates of constipation, nausea, vomiting, leukopenia, neutropenia Ⅲ-Ⅳ degrees reaction were 13.75%, 10.00%, 15.00%, 13.75%, and the overall incidence rates were 41.25%, 42.50%, 41.25%, 43.75% respectively. Conclusion Epirubicin joint docetaxel adjuvant chemotherapy has good short term efficacy for triple negative breast cancer, but its long-term efficacy is poor to non-triple-negative breast cancer. Key words: Breast neoplasms; Epirubicin; Docetaxel